Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment
Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial Paris […]